IL6 and synovial sarcoma: SOCS3 downregulation may lead to enhanced activity of pro-inflammatory IL6 family cytokines through its reduced ability to interact with gp130 (56) to modulate IL6 signaling, also potentially contributing to SS pathogenesis.